Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16773355 | 0.95 | KDM4E (0.43) | KDM4EATML3MBTL1JAK2JAK3 | |
| SCHEMBL15582829 | 0.94 | KDM4E (0.44) | KDM4EATML3MBTL1JAK2JAK3 | |
| SCHEMBL16870118 | 0.91 | KDM4E (0.41) | KDM4EATML3MBTL1JAK2JAK3 | |
| SCHEMBL10027541 | 0.91 | KDM4E (0.46) | KDM4EATML3MBTL1JAK2JAK3 | |
| SCHEMBL26050290 | 0.91 | KDM4E (0.46) | KDM4EATML3MBTL1JAK2JAK3 | |
| SCHEMBL16773634 | 0.90 | KDM4E (0.45) | KDM4EATML3MBTL1JAK2JAK3 | |
| SCHEMBL26050182 | 0.90 | KDM4E (0.37) | KDM4EATML3MBTL1 | |
| SCHEMBL16773354 | 0.90 | L3MBTL1 (0.40) | KDM4EATML3MBTL1JAK2JAK3 | |
| SCHEMBL17189529 | 0.89 | KDM4E (0.50) | KDM4EATML3MBTL1JAK2JAK3 | |
| SCHEMBL31795 | 0.89 | KDM4E (0.50) | KDM4EATML3MBTL1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697645-B2 | Heterocyclic compound, composition including heterocyclic compound, and organic light-emitting device including heterocyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-07-11 | — | — | US | disclosed |
| US-11697645-B2 | Heterocyclic compound, composition including heterocyclic compound, and organic light-emitting device including heterocyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-07-11 | — | — | US | disclosed |
| US-20230140682-A1 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-05-04 | — | — | US | disclosed |
| US-20230140682-A1 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-05-04 | — | — | US | disclosed |
| US-11542252-B2 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-01-03 | — | — | US | disclosed |
| US-20200207732-A1 | HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING HETEROCYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-07-02 | — | — | US | disclosed |
| US-20200207739-A1 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-07-02 | — | — | US | disclosed |
| US-20200212307-A1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-07-02 | — | — | US | disclosed |
| US-9680111-B2 | Compositions for electronic applications | E I DU PONT DE NEMOURS AND COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
| US-9680111-B2 | Compositions for electronic applications | E I DU PONT DE NEMOURS AND COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160164005-A1 | COMPOSITIONS FOR ELECTRONIC APPLICATIONS | LG CHEM, LTD. (KR) | 2016-06-09 | — | — | US | disclosed |
| US-9293716-B2 | Compositions for electronic applications | EI DU PONT DE NEMOURS AND COMPANY (US) | 2016-03-22 | — | — | US | disclosed |
| US-9293716-B2 | Compositions for electronic applications | EI DU PONT DE NEMOURS AND COMPANY (US) | 2016-03-22 | — | — | US | disclosed |
| US-9293716-B2 | Compositions for electronic applications | EI DU PONT DE NEMOURS AND COMPANY (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2655547-A1 | COMPOSITIONS FOR ELECTRONIC APPLICATIONS | E.I. Du Pont De Nemours And Company (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130248849-A1 | COMPOSITIONS FOR ELECTRONIC APPLICATIONS | E I DUPONT DE NEMOURS AND COMPANY (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130248849-A1 | COMPOSITIONS FOR ELECTRONIC APPLICATIONS | E I DUPONT DE NEMOURS AND COMPANY (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130248849-A1 | COMPOSITIONS FOR ELECTRONIC APPLICATIONS | E I DUPONT DE NEMOURS AND COMPANY (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012087955-A1 | COMPOSITIONS FOR ELECTRONIC APPLICATIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087955-A1 | COMPOSITIONS FOR ELECTRONIC APPLICATIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697645-B2 | Heterocyclic compound, composition including heterocyclic compound, and organic light-emitting device including heterocyclic compound | CYP1B1, CYP1A1, CCNT1 | KDM4E 4155/4885ATM 1467/4885L3MBTL1 517/4885 |
| US-11542252-B2 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | CCNT1, CCNA1, CYP1B1 | KDM4E 3931/4885ATM 1887/4885L3MBTL1 175/4885 |
| US-20200207732-A1 | HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING HETEROCYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND | CYP1B1, CYP1A1, CCNT1 | KDM4E 4155/4885ATM 1467/4885L3MBTL1 517/4885 |
| US-20230140682-A1 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | CCNT1, CCNA1, CYP1B1 | KDM4E 3931/4885ATM 1887/4885L3MBTL1 175/4885 |
| US-20200212307-A1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND | CCNB1, CCNA1, CCNT1 | KDM4E 4280/4885ATM 827/4885L3MBTL1 285/4885 |
| US-20200207739-A1 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | CCNT1, CCNA1, CYP1B1 | KDM4E 3931/4885ATM 1887/4885L3MBTL1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.